PMID- 32218807
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 1758-8340 (Print)
IS  - 1758-8359 (Electronic)
IS  - 1758-8340 (Linking)
VI  - 12
DP  - 2020
TI  - An open label, multicenter, noninterventional study of apatinib in advanced 
      gastric cancer patients (AHEAD-G202).
PG  - 1758835920905424
LID - 10.1177/1758835920905424 [doi]
LID - 1758835920905424
AB  - BACKGROUND: Apatinib has been proved to be effective and well tolerated among 
      patients in phase II and III studies. Here, we evaluated the safety and 
      effectiveness of apatinib in advanced gastric cancer patients in a real-world 
      setting. METHODS: This study enrolled advanced gastric cancer patients who had 
      progressed or relapsed despite systemic chemotherapy. The primary outcome was 
      safety and the secondary outcomes included overall survival (OS) and 
      progression-free survival (PFS). RESULTS: A total of 337 patients were included. 
      In total, 62 (18.4%), 102 (30.3%), and 173 (51.3%) patients received first, 
      second, and third or higher line apatinib therapy, respectively. Grade 3/4 
      treatment-emergent adverse events (AEs) were infrequent (<5%), with hypertension 
      (6.8%) being the only grade 3/4 AE occurring in more than 5% of the patients and 
      across the low-dose (250 mg, 7.3%), mid-dose (425-500 mg, 6.1%), and high-dose 
      group (675-850 mg, 2/15, 13.3%). The median OS and PFS were 7.13 months (95% CI, 
      6.17-7.93) and 4.20 months (95% CI, 4.60-4.77), respectively, and were comparable 
      among the low-, mid-, and high-dose groups. CONCLUSION: Lower daily doses of 
      apatinib achieved comparable OS and PFS versus higher daily doses of apatinib 
      while maintaining a more benign safety profile in advanced gastric cancer 
      patients. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: 
      NCT02668380.
CI  - (c) The Author(s), 2020.
FAU - Wang, Xiang
AU  - Wang X
AD  - Department of Medical Oncology, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences, Beijing, China.
FAU - Zhang, Ruixing
AU  - Zhang R
AD  - Department of Gastroenterology, The Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Du, Nan
AU  - Du N
AD  - Department of Medical Oncology, Fourth Medical Center of PLA General Hospital, 
      Beijing, China.
FAU - Yang, Mudan
AU  - Yang M
AD  - Digestive Department of Oncology, Shanxi Tumor Hospital, Taiyuan, China.
FAU - Zang, Aimin
AU  - Zang A
AD  - Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, 
      China.
FAU - Liu, Likun
AU  - Liu L
AD  - Oncology Department, Shanxi Provincial Hospital of Traditional Chinese Medicine, 
      Taiyuan, China.
FAU - Yu, Junyan
AU  - Yu J
AD  - Department of Oncology, Peace Hospital of Changzhi Medical College, Changzhi, 
      China.
FAU - Gao, Jinghua
AU  - Gao J
AD  - Department of Medical Oncology, Cangzhou Central Hospital, Cangzhou, China.
FAU - Zhang, Junping
AU  - Zhang J
AD  - Department of Medical Oncology, Shanxi Academy of Medical Sciences, Shanxi Dayi 
      Hospital, Taiyuan, China.
FAU - Fu, Zhanzhao
AU  - Fu Z
AD  - Department of Medical Oncology, First Hospital of Qinhuangdao, Qinhuangdao, 
      China.
FAU - Ren, Yuchuan
AU  - Ren Y
AD  - Oncology Department, Yangquan First People's Hospital, Yangquan, China.
FAU - Ma, Liwen
AU  - Ma L
AD  - Department of Tumor Chemotherapy and Radiology, Peking University Third Hospital, 
      Beijing, China.
FAU - Guo, Jun
AU  - Guo J
AD  - Department of Medical Oncology, Xingtai People's Hospital, Hebei Medical 
      University Affiliated Hospital, Xingtai, China.
FAU - Li, Qingshan
AU  - Li Q
AD  - Department of Medical Oncology, Affiliated Hospital of Chengde Medical 
      University, Chengde, China.
FAU - Li, Xiaomei
AU  - Li X
AD  - Department of Medical Oncology, Chinese PLA General Hospital, Medical School of 
      Chinese PLA, Beijing, China.
FAU - Fan, Zaiwen
AU  - Fan Z
AD  - Department of Medical Oncology, Air Force General Hospital, PLA, Beijing, China.
FAU - Song, Xiang
AU  - Song X
AD  - Department of Medical Oncology, Second Hospital of Shanxi Medical University, 
      Taiyuan, China.
FAU - Liu, Zheng
AU  - Liu Z
AD  - Department of Radiology, Handan Central Hospital, Handan, China.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - Department of Medical Oncology, Shijiazhuang People's Hospital, Shijiazhuang, 
      China.
FAU - Li, Guozhong
AU  - Li G
AD  - Department of Medical Oncology, Peking University Binhai Hospital, Tianjin, 
      China.
FAU - Yu, Zhonghe
AU  - Yu Z
AD  - Department of Medical Oncology, Seventh Medical Center of PLA General Hospital, 
      Beijing, China.
FAU - Diao, Jianfeng
AU  - Diao J
AD  - Department of Medical Oncology, Datong Second People's Hospital, Datong, China.
FAU - Jia, Junmei
AU  - Jia J
AD  - Department of Medical Oncology, First Hospital of Shanxi Medical University, 
      Taiyuan, China.
FAU - Liang, Feng
AU  - Liang F
AD  - Department of General Surgery, Fifth Medical Center of PLA General Hospital, 
      Beijing, China.
FAU - Wang, Huaqing
AU  - Wang H
AD  - Department of Medical Oncology, Tianjin People's Hospital, Tianjin, China.
FAU - Sun, Junzhong
AU  - Sun J
AD  - Department of Medical Oncology, Fourth Medical Center of PLA General Hospital, 
      Beijing, China.
FAU - Gao, Yunge
AU  - Gao Y
AD  - Department of Hematology and Oncology, Strategic Support Force Characteristic 
      Medical Center/Former The 306 Hospital of PLA, Beijing, China.
FAU - Yang, Ping
AU  - Yang P
AD  - Department of Medical Oncology, Sixth Medical Center of PLA General Hospital, 
      Beijing, China.
FAU - Bai, Chunmei
AU  - Bai C
AUID- ORCID: 0000-0003-1333-9145
AD  - Department of Medical Oncology, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences, No.1 Shuaifuyuan Wangfujing Dongcheng District, 
      Beijing 100032, China.
FAU - Ren, Xiubao
AU  - Ren X
AD  - Department of Biotherapy, Tianjin Medical University Cancer Institute and 
      Hospital, Tianjin 300060, China.
FAU - Zhong, Diansheng
AU  - Zhong D
AD  - Department of Medical Oncology, Tianjin Medical University General Hospital, 
      Tianjin 300052, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT02668380
PT  - Journal Article
DEP - 20200319
PL  - England
TA  - Ther Adv Med Oncol
JT  - Therapeutic advances in medical oncology
JID - 101510808
PMC - PMC7082876
OTO - NOTNLM
OT  - apatinib
OT  - effectiveness
OT  - gastric cancer
OT  - real world
OT  - safety
COIS- Conflict of interest statement: The authors declare that there is no conflict of 
      interest.
EDAT- 2020/03/29 06:00
MHDA- 2020/03/29 06:01
PMCR- 2020/03/19
CRDT- 2020/03/29 06:00
PHST- 2019/07/23 00:00 [received]
PHST- 2020/01/14 00:00 [accepted]
PHST- 2020/03/29 06:00 [entrez]
PHST- 2020/03/29 06:00 [pubmed]
PHST- 2020/03/29 06:01 [medline]
PHST- 2020/03/19 00:00 [pmc-release]
AID - 10.1177_1758835920905424 [pii]
AID - 10.1177/1758835920905424 [doi]
PST - epublish
SO  - Ther Adv Med Oncol. 2020 Mar 19;12:1758835920905424. doi: 
      10.1177/1758835920905424. eCollection 2020.